Lumos Diagnostics
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Lumos Diagnostics sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Lumos Diagnostics: 6 sponsored US clinical trials, 1 recruiting.
Lumos Diagnostics sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. The most-studied condition in this pipeline is SARS-CoV-2, with 1 trials.
Upper-quartile sponsor footprint
Lumos Diagnostics sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
FebriDx® Pediatric Validation Study
NCT07211997
FebriDx® Method Comparison Study Protocol
NCT06746259
PheCheck Feasibility Study
NCT05998109
Clinical Evaluation of a COVID-19 Antigen Self-Test (CoviDx™)
NCT05403346
Clinical Evaluation of a Point-of-Care (POC), COVID-19 Rapid Antigen Test (CoviDx™)
NCT04750629
Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood
NCT04699903
Therapeutic Areas
What is open in the Lumos Diagnostics pipeline
1 recruiting of 6 indexed (17% open); 4 completed (67%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: SARS-CoV-2 (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Lumos Diagnostics: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Lumos Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Lumos Diagnostics page
6 registered trials is a research-attention snapshot, not an endorsement of Lumos Diagnostics or any single study.
- 1 of Lumos Diagnostics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- SARS-CoV-2 is the condition Lumos Diagnostics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See SARS-CoV-2 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Lumos Diagnostics pipeline card: 6 registered trials from official public datasets.Report a data error.